192 related articles for article (PubMed ID: 8808461)
1. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
[TBL] [Abstract][Full Text] [Related]
2. Immunological studies in uremic and kidney transplanted patients.
Langhoff E
Dan Med Bull; 1989 Apr; 36(2):160-75. PubMed ID: 2651030
[TBL] [Abstract][Full Text] [Related]
3. [Examination of lymphokines in patients with hemodialysis (author's transl)].
Löcsey L; Kálmán K; Hauck M; Kakuk G
Allerg Immunol (Leipz); 1979; 25(3):211-7. PubMed ID: 162030
[TBL] [Abstract][Full Text] [Related]
4. The influence of uremic sera on the blastic transformation of lymphocytes of healthy subjects, stimulated with non-specific mitogens (PHA, con A, PWM).
Klinger M; Kuczera J; Kruzel E
Arch Immunol Ther Exp (Warsz); 1980; 28(1):73-82. PubMed ID: 7416921
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin A and prednisolone: an additive inhibitory effect of cell proliferation and interleukin-2 production.
Manfro RC; Pohanka E; Tomlanovich S; Benet LZ; Garovoy MR
Transplant Proc; 1989 Feb; 21(1 Pt 2):1457-9. PubMed ID: 2523586
[No Abstract] [Full Text] [Related]
6. The effect of the alpha 2-HS-glycoprotein on the mitogen-induced lymphoblastic transformation and IL-2 production.
Jakab L; Jakab L; Kalabay L; Pozsonyi T; Cseh K
Acta Physiol Hung; 1991; 77(1):25-31. PubMed ID: 1950589
[TBL] [Abstract][Full Text] [Related]
7. The effects of uremic serum and 3'-5' cyclic AMP on blastogenesis of normal lymphocytes.
Modai D; Weissgarten J; Cohen N; Averbukh Z; Golik A; Peller S; Tieder M; Shaked U; Kaufman S
Thymus; 1986; 8(5):307-11. PubMed ID: 3026066
[TBL] [Abstract][Full Text] [Related]
8. In vitro reactivity of lymphocytes obtained from uraemic patients maintained by heamodialysis.
Sengar DP; Rashid A; Harris JE
Clin Exp Immunol; 1975 Aug; 21(2):298-305. PubMed ID: 126831
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance.
Walker KB; Potter JM; House AK
Clin Exp Immunol; 1987 Apr; 68(1):162-7. PubMed ID: 3498565
[TBL] [Abstract][Full Text] [Related]
11. The effects of varying dialysis regimens on lymphocyte stimulation.
Hurst KS; Saldanha LF; Steinberg SM; Galen MA; Lowrie EG; Gagneux SA; Lazarus JM; Strom TB; Carpenter CB; Merrill JP
Trans Am Soc Artif Intern Organs; 1975; 21():329-34. PubMed ID: 1146004
[TBL] [Abstract][Full Text] [Related]
12. In vitro immune functions in patients with minor, moderate, and severe kidney impairment.
Langhoff E; Ladefoged J
APMIS; 1988 Jul; 96(7):655-9. PubMed ID: 3261594
[TBL] [Abstract][Full Text] [Related]
13. Effect of interleukin-2 and methylprednisolone on in vitro transformation of uremic lymphocytes.
Langhoff E; Ladefoged J; Odum N
Int Arch Allergy Appl Immunol; 1986; 81(1):5-11. PubMed ID: 3488966
[TBL] [Abstract][Full Text] [Related]
14. Systemic heparinization of uremic patients and its effects on blood lipids and on in vitro toxicity of the plasma.
Wessel-Aas T; Christophersen B
Clin Nephrol; 1982 Sep; 18(3):135-40. PubMed ID: 7140025
[TBL] [Abstract][Full Text] [Related]
15. Synergetic effect of dialyzer membrane and lipopolysaccharide on peripheral blood mononuclear cell cytokine production in uremic patients.
Gu Y; Ding F; Qin H; Zhao H; Lin S
Chin Med J (Engl); 2000 Apr; 113(4):315-9. PubMed ID: 11775226
[TBL] [Abstract][Full Text] [Related]
16. Immune deficiency of the uremic patient.
Chatenoud L; Herbelin A; Beaurain G; Descamps-Latscha B
Adv Nephrol Necker Hosp; 1990; 19():259-74. PubMed ID: 2105582
[No Abstract] [Full Text] [Related]
17. Fractions of middle molecular weight responsible for immunodeficiency in malnourished and burnt patients.
Gay G; Touraine JL; Touraine F; Freyria AM; Traeger J; Navarro J
Artif Organs; 1981; 4 Suppl():71-5. PubMed ID: 6794551
[TBL] [Abstract][Full Text] [Related]
18. In vitro cytotoxic properties of plasma samples from uremic patients.
Delaporte C; Gros F; Jonsson C; Bergström J
Clin Nephrol; 1982 May; 17(5):247-53. PubMed ID: 7094441
[TBL] [Abstract][Full Text] [Related]
19. The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells.
Higuchi T; Fukuda N; Yamamoto C; Yamazaki T; Oikawa O; Ohnishi Y; Okada K; Soma M; Matsumoto K
Ther Apher Dial; 2006 Feb; 10(1):65-71. PubMed ID: 16556139
[TBL] [Abstract][Full Text] [Related]
20. MLC-blocking factors in uremic sera.
Fehrman I; Ringdén O; Bergström J
Clin Nephrol; 1980 Oct; 14(4):183-9. PubMed ID: 7000408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
